RxDoctor Payments Data

David Cannon, MD

Internal Medicine · Lynchburg, VANPI 1891778387

Payments from drug & device makers

$1,014in general payments, 2019–2025

Across 62 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$238
  • Abbott$190
  • Novo Nordisk$119
  • Insightec,inc$111
  • Johnson & Johnson$106
  • Xeris Pharmaceuticals, Inc.$96
  • plus $154 from 5 others

What the payments were for

  • Food & beverage$1,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,014 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$330,215
Medicare patients
635
Services billed
8,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$101,612
JanuviaSitagliptin Phosphate46$58,571
OzempicSemaglutide40$56,003
XareltoRivaroxaban28$35,755
JardianceEmpagliflozin17$22,727
TrulicityDulaglutide13$22,033
EntrestoSacubitril/Valsartan12$12,543
LinzessLinaclotide15$12,150
FarxigaDapagliflozin Propanediol16$9,590
MyrbetriqMirabegron12$6,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,320
Atorvastatin Calcium552$5,178
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,901
Levothyroxine Sodium464$4,665
Losartan Potassium328$3,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$101,61275 claims
Novo NordiskOzempic$119$56,00340 claims
Johnson & JohnsonXarelto$106$35,75528 claims
AbbVieLinzess, Synthroid$238$14,59079 claims
NovartisEntresto$18$12,54312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →